Konstantinos Papamichail, M.D., Ph.D.

Dr. Konstantinos Papamichail is a physician-scientist internationally recognized for his innovative research in the field of therapeutic drug monitoring (TDM) of biologic therapy in IBD. Dr. Papamichail joined the Center of IBD at BIDMC in 2015 following a 3-year post-doctoral Research Fellowship in the Leuven IBD group in Belgium under the supervision of Prof. Severine Vermeire. Dr. Papamichail is invited to lecture both nationally and internationally and has received numerous awards and distinctions including the prestigious Fellowship Grant from the European Crohn’s and Colitis Organization (ECCO).

He was a member of the Scientific Committee (SciCom) of ECCO and he is currently a member of the Research Committee of the American College Gastroenterology (ACG). Dr. Papamichail is also an Editorial Board member of the Journal of Crohn’s and Colitis and the Journal of Clinical Medicine. Dr. Papamichail has published more than 155 papers with a Google Scholar h-index of 45.

Drs. Cheifetz and Papamichail are well known for their novel research on the role of proactive TDM of anti-TNF-therapy in IBD showing that proactive TDM is associated with better therapeutic outcomes compared to empiric treatment optimization and/or reactive TDM. They were also leading members in a Consensus Meeting and first co-authors of a collaborative paper, published in Clinical Gastroenterology and Hepatology, of the Building Research in IBD Globally (BRIDGe) group on how to better apply TDM in clinical practice. Based on this publication, the BRIDGe Biologic Therapy Optimizer was developed to help providers improve the efficacy and safety of biologic therapy and better treat IBD patients.